Shun Lu

2.1k total citations
51 papers, 893 citations indexed

About

Shun Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shun Lu has authored 51 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Shun Lu's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Genomics and Diagnostics (8 papers). Shun Lu is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Cancer Genomics and Diagnostics (8 papers). Shun Lu collaborates with scholars based in China, United States and Spain. Shun Lu's co-authors include Xiaomin Niu, Yunhua Xu, Ziming Li, Xiangyun Ye, Ziming Li, Zhiwei Chen, Enriqueta Felip, Wenxiang Ji, Ying Yang and Tingting Lü and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Shun Lu

48 papers receiving 882 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shun Lu China 17 395 345 304 161 80 51 893
Liang‐Ru Ke China 18 291 0.7× 98 0.3× 239 0.8× 125 0.8× 112 1.4× 37 767
Chan‐Young Ock South Korea 17 508 1.3× 276 0.8× 249 0.8× 150 0.9× 90 1.1× 98 989
Jianguo Zhang China 21 189 0.5× 405 1.2× 678 2.2× 406 2.5× 97 1.2× 80 1.2k
Yuka Asano Japan 23 1.0k 2.6× 289 0.8× 278 0.9× 470 2.9× 255 3.2× 111 1.6k
Özlem Yersal Türkiye 9 420 1.1× 160 0.5× 421 1.4× 338 2.1× 50 0.6× 15 994
Xiaohong Huang China 15 182 0.5× 64 0.2× 294 1.0× 89 0.6× 52 0.7× 26 734
Yanning Yang China 16 161 0.4× 135 0.4× 250 0.8× 162 1.0× 28 0.3× 36 662
Elham Sajjadi Italy 20 654 1.7× 240 0.7× 262 0.9× 285 1.8× 95 1.2× 55 1.0k
Chunguang Li China 18 258 0.7× 166 0.5× 549 1.8× 330 2.0× 55 0.7× 48 960

Countries citing papers authored by Shun Lu

Since Specialization
Citations

This map shows the geographic impact of Shun Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shun Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shun Lu more than expected).

Fields of papers citing papers by Shun Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shun Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shun Lu. The network helps show where Shun Lu may publish in the future.

Co-authorship network of co-authors of Shun Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Shun Lu. A scholar is included among the top collaborators of Shun Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shun Lu. Shun Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yin, Liliang Xia, Hui Wang, et al.. (2025). Single-cell spatial proteomics of non-relapse small cell lung cancer identifies tumor microenvironment determinants of survival. Cell Biology and Toxicology. 41(1). 106–106.
2.
Lu, Shun, Fabrice Barlési, Robert M. Jotte, et al.. (2024). OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12. Journal of Thoracic Oncology. 19(10). S30–S30. 2 indexed citations
3.
Barlési, Fabrice, M. Duruisseaux, Ludovic Doucet, et al.. (2024). LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12. Annals of Oncology. 35. S1247–S1248. 7 indexed citations
4.
Lu, Shun, et al.. (2023). Sweet Gradient matters: Designing consistent and efficient estimator for Zero-shot Architecture Search. Neural Networks. 168. 237–255. 1 indexed citations
5.
Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310. 37 indexed citations
6.
Provencio, Mariano, Patrick M. Forde, C. Wang, et al.. (2023). LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression. Annals of Oncology. 34. S1298–S1299. 13 indexed citations
7.
Wang, Changli, Ke‐Neng Chen, Qixun Chen, et al.. (2023). Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816. Cancer Research. 83(8_Supplement). CT081–CT081. 1 indexed citations
8.
Lu, Shun, Yu Hu, Peihao Wang, et al.. (2023). PINAT: A Permutation INvariance Augmented Transformer for NAS Predictor. Proceedings of the AAAI Conference on Artificial Intelligence. 37(7). 8957–8965. 8 indexed citations
9.
Lu, Shun, et al.. (2023). Object Detection for UAV Aerial Scenarios Based on Vectorized IOU. Sensors. 23(6). 3061–3061. 9 indexed citations
10.
Lü, Min, Kaixuan Wang, Wenxiang Ji, et al.. (2022). FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma. Cellular Immunology. 379. 104577–104577. 10 indexed citations
11.
Chu, Xiangxiang, Xiaoxing Wang, Bo Zhang, et al.. (2021). DARTS-: Robustly Stepping out of Performance Collapse Without Indicators. International Conference on Learning Representations. 35 indexed citations
12.
Lu, Shun, Jixiang Li, Jianchao Tan, Sen Yang, & Ji Liu. (2021). TNASP: A Transformer-based NAS Predictor with a Self-evolution Framework. Neural Information Processing Systems. 34. 9 indexed citations
13.
Ai, Xinghao, Jiuwei Cui, Jiexia Zhang, et al.. (2020). Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clinical Cancer Research. 27(3). 704–712. 31 indexed citations
14.
Lü, Tingting, Ying Yang, Ziming Li, & Shun Lu. (2020). MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1. Cancer Cell International. 20(1). 413–413. 16 indexed citations
15.
Zhou, Zhen, Shun Lu, Shukui Qin, et al.. (2020). 388P Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients. Annals of Oncology. 31. S1393–S1394. 2 indexed citations
16.
Chu, Qian, Xun Yuan, Wenxiang Ji, et al.. (2016). A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. International Journal of Nanomedicine. 11. 2119–2119. 26 indexed citations
17.
Tan, Qiang, Jian Cui, Jia Huang, et al.. (2016). Genomic Alteration During Metastasis of Lung Adenocarcinoma. Cellular Physiology and Biochemistry. 38(2). 469–486. 21 indexed citations
18.
Chen, Zhiwei, Bin Liu, Yunhua Xu, et al.. (2014). FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response. Nucleic Acids Research. 42(18). 11560–11569. 29 indexed citations
19.
Zhou, Min, Hai Wang, Keke Zhou, et al.. (2013). A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells. Cancer Research. 73(23). 7056–7067. 20 indexed citations
20.
Shen, Lan, Ziming Li, Shengping Shen, et al.. (2012). The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Lung Cancer. 78(3). 193–200. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liang‐Ru Ke Breakdown of academic impact, for papers by Chan‐Young Ock Breakdown of academic impact, for papers by Jianguo Zhang Breakdown of academic impact, for papers by Yuka Asano Breakdown of academic impact, for papers by Özlem Yersal Breakdown of academic impact, for papers by Xiaohong Huang Breakdown of academic impact, for papers by Yanning Yang Breakdown of academic impact, for papers by Elham Sajjadi Breakdown of academic impact, for papers by Chunguang Li
Rankless by CCL
2026